Literature DB >> 29542222

Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis.

C M van Driel1,2, A Stuursma1,2, M J Schroevers3, M J Mourits1, G H de Bock2.   

Abstract

BACKGROUND: During menopause women experience vasomotor and psychosexual symptoms that cannot entirely be alleviated with hormone replacement therapy (HRT). Besides, HRT is contraindicated after breast cancer.
OBJECTIVES: To review the evidence on the effectiveness of psychological interventions in reducing symptoms associated with menopause in natural or treatment-induced menopausal women. SEARCH STRATEGY: Medline/Pubmed, PsycINFO, EMBASE and AMED were searched until June 2017. SELECTION CRITERIA: Randomised controlled trials (RCTs) concerning natural or treatment-induced menopause, investigating mindfulness or (cognitive-)behaviour-based therapy were selected. Main outcomes were frequency of hot flushes, hot flush bother experienced, other menopausal symptoms and sexual functioning. DATA COLLECTION AND ANALYSIS: Study selection and data extraction were performed by two independent researchers. A meta-analysis was performed to calculate the standardised mean difference (SMD). MAIN
RESULTS: Twelve RCTs were included. Short-term (<20 weeks) effects of psychological interventions in comparison to no treatment or control were observed for hot flush bother (SMD -0.54, 95% CI -0.74 to -0.35, P < 0.001, I2  = 18%) and menopausal symptoms (SMD -0.34, 95% CI -0.52 to -0.15, P < 0.001, I2  = 0%). Medium-term (≥20 weeks) effects were observed for hot flush bother (SMD -0.38, 95% CI -0.58 to -0.18, P < 0.001, I2  = 16%). [Correction added on 9 July 2018, after first online publication: there were miscalculations of the mean end point scores for hot flush bother and these have been corrected in the preceding two sentences.] In the subgroup treatment-induced menopause, consisting of exclusively breast cancer populations, as well as in the subgroup natural menopause, hot flush bother was reduced by psychological interventions. Too few studies reported on sexual functioning to perform a meta-analysis.
CONCLUSIONS: Psychological interventions reduced hot flush bother in the short and medium-term and menopausal symptoms in the short-term. These results are especially relevant for breast cancer survivors in whom HRT is contraindicated. There was a lack of studies reporting on the influence on sexual functioning. TWEETABLE ABSTRACT: Systematic review: psychological interventions reduce bother by hot flushes in the short- and medium-term.
© 2018 The Authors. BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd on behalf of Royal College of Obstetricians and Gynaecologists.

Entities:  

Keywords:  Behavioural therapy; cognitive behavioural therapy; menopause; mindfulness; sexual functioning; vasomotor symptoms

Mesh:

Year:  2018        PMID: 29542222      PMCID: PMC6585818          DOI: 10.1111/1471-0528.15153

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


Introduction

Menopause can occur either naturally or can be induced by treatments such as pelvic radiation, oophorectomy, endocrine therapy or chemotherapy.1, 2 Menopausal symptoms are experienced frequently with up to 85% of menopausal women reporting vasomotor symptoms (i.e. hot flushes and night sweats), up to 60% reporting vaginal discomfort (i.e. vaginal dryness and/or dyspareunia), and up to 87% reporting sexual dysfunction (e.g. lack of sexual desire and difficulty reaching orgasm).3, 4, 5 Moreover, women who experience treatment‐induced menopause report more severe symptom levels than women experiencing natural menopause.6, 7 To reduce the aforementioned symptoms, hormone replacement therapy (HRT) is currently the most effective option.8, 9 However, the use of HRT in postmenopausal women is associated with increased breast cancer risk and contraindicated in breast cancer survivors.10, 11 Furthermore, HRT only partially relieves symptoms, symptom levels remain higher than in premenopausal women and especially sexual discomfort is not alleviated.12 Therefore, safe nonhormonal alternatives to HRT are needed, in particular for breast cancer survivors such as young BRCA1/2 mutation carriers after breast cancer and risk‐reducing salpingo‐oophorectomy. Nonhormonal options to decrease the frequency and bother of hot flushes include stress‐reducing psychological interventions such as cognitive behavioural therapy (CBT), behavioural therapy (BT) and mindfulness‐based therapies (MBT).13 The possible mechanism of action of these interventions is that they reduce stress. Stress is thought to lower the threshold for heat dissipation responses14, 15 and therefore can potentiate a hot flush.16 It is proposed that CBT, BT and MBT diminish this trigger by reducing stress, so reducing the frequency of hot flushes. An additional mechanism of action of the above‐mentioned interventions might be that by modifying cognitive appraisals of hot flushes, the bother caused by hot flushes can be decreased.13 Several large randomised controlled trials (RCTs) that were recently published have investigated the effect of CBT, MBT and BT on hot flushes and other menopausal symptoms.17, 18, 19, 20 The aim of this systematic review and meta‐analysis is to add a quantitative examination of the existing evidence on the effectiveness of psychological interventions in reducing symptoms associated with menopause in women with natural or treatment‐induced menopause.

Methods

The conduct and reporting of this systematic literature review and meta‐analysis was based on the Preferred Reporting Items for Systematic Reviews and Meta‐analysis (PRISMA) statement.21 First, studies were screened for eligibility based on their titles and abstract. Full texts of possibly eligible studies were retrieved after the initial screening for more detailed evaluation. Second, two review authors (CD and AS) independently performed a final selection of studies, assessed the risk of bias and extracted data from the full‐text papers using a prespecified form. The following data were extracted with the use of these forms: population (e.g. sample size, natural or treatment‐induced menopause), intervention (e.g. type of intervention, duration, length of programme), control group, co‐interventions and outcomes (e.g. frequency and bother of hot flushes, menopausal symptoms, sexual functioning and adverse effects). Of the outcomes, the time‐points of measurement and results such as means and measure of variance were extracted. Menopausal symptoms were defined as the combined level of burden from a broad range of symptoms related to menopause such as psychosocial symptoms (e.g. irritability, forgetfulness), physical symptoms (e.g. joint pain, headaches), genital symptoms (e.g. dryness, itching), sexual dysfunction and vasomotor symptoms. Electronic databases that were searched are Medline/Pubmed, EMBASE, PsycINFO and AMED. Other search methods used were reference checking of selected studies and of existing reviews on adjacent topics. Search terms of the electronic literature search are provided in the (Table S1). The initial search was conducted in February 2016 and an updated search was performed in June 2017. Risk of bias was assessed with the risk of bias tool from the Cochrane collaboration,22 see (Table S2). Disagreements on inclusion of studies, extracted data or risk of bias assessments was solved by consensus between the two review authors (CD and AS). If consensus was not reached the other authors were consulted (GB, MS and MM). The protocol of this systematic literature review and meta‐analysis is registered in the PROSPERO database (CRD42016038135).

Eligibility criteria

Studies considered eligible were RCTs with a published full text in English evaluating the effect of CBT, BT or MBT on either naturally occurring or treatment‐induced hot flushes, menopausal symptoms or sexual functioning compared with a waiting list or with ‘care as usual’ (e.g. lifestyle advice, breast cancer follow up). Menopause did not have to be formally established (e.g. by amenorrhea >12 months or laboratory tests), but could be based on patient‐reported signs and symptoms of menopause. The intervention could either consist of group or individual therapy and could be a general programme or could be specifically tailored to symptoms associated with menopause. Only patient‐reported outcomes were included. Studies were excluded if interventions were limited to yoga, hypnosis, exercise, meditation, awareness training or breathing techniques as a stand‐alone therapy, because these interventions were either not based on a stress‐reducing mechanism of action or were not based on widely used protocolled standards. Studies were also excluded if there was no face‐to‐face therapeutic contact with a therapist or trainer during the study (e.g. web‐based interventions). Use of HRT in the intervention and/or control group was allowed. However, studies that specifically aimed to use HRT as the control condition were excluded. Lastly, studies were excluded if the outcomes were physical measures (e.g. sternal skin conductance) only. The rationale behind favouring patient‐reported outcomes over physical measures was that patient‐reported hot flush frequency could be more closely related to actual inconvenience caused by hot flushes as patient‐reported hot flush frequency measures the perceptual aspect, whereas physical measures assess the physiological aspect of the hot flush construct.23 Therefore we deemed patient‐reported outcomes to be of more interest for clinical practice.

Statistical analysis

The following outcomes were considered at short‐term (<20 weeks after randomisation) and at medium‐term (≥20 weeks after randomisation): frequency and bother of hot flushes, menopausal symptoms and sexual functioning. A random effects meta‐analysis using inverse variance method was performed. Using mean end points and standard deviations (SDs), per study a standardised mean difference (SMD) with a 95% CI was calculated for all outcomes. Effect size was defined as small (0.2), medium (0.5) or large (0.8).24 Heterogeneity was assessed per outcome with I 2, chi‐square test and P‐value. Funnel plots were made to assess publication bias. Asymmetrical funnel plots indicate a higher risk of publication bias.22 Asymmetry was assessed using Egger's test, which was interpreted using a cut‐off value of 0.10.25 As the effect of the interventions could differ for treatment‐induced and natural menopausal symptoms, a subgroup analysis was performed for natural menopause versus treatment‐induced menopause when two or more studies were available per subgroup for an outcome. All analyses were performed using review manager (RevMan version 5.3.5.).

Results

Selection of studies

A flow diagram of the study selection is shown in Figure 1. Based on the title and abstract screening, 24 records were eligible for full‐text assessment, of which 12 records did not meet the eligibility criteria. So, the final number of included studies in the qualitative synthesis was 12. Of the included studies, ten studies could be included in the main quantitative synthesis (meta‐analysis), as two studies only reported medians because of possible skewness of the data.26, 27 An overview of studies reporting medians compared with studies in the main meta‐analysis is shown in Figure 2.
Figure 1

Flow diagram of study selection.

Figure 2

Forrest plot of hot flush frequency, hot flush bother, menopausal symptoms and sexual functioning for both short‐term (<20 weeks) and medium‐term (≥20 weeks) results, split for mean and median outcomes. CI, confidence interval; IV, inverse variance; SD, standard deviation; Std, standardized. [Correction added on 9 July 2018, after first online publication: Figure 2 was incorrect and has been replaced in this version.]

Flow diagram of study selection. Forrest plot of hot flush frequency, hot flush bother, menopausal symptoms and sexual functioning for both short‐term (<20 weeks) and medium‐term (≥20 weeks) results, split for mean and median outcomes. CI, confidence interval; IV, inverse variance; SD, standard deviation; Std, standardized. [Correction added on 9 July 2018, after first online publication: Figure 2 was incorrect and has been replaced in this version.]

Characteristics of included studies

The total size of study population per study varied from 16 to 214 women (Table 1). The combined sample size of all studies consisting of participants in the control and intervention groups was 1016 women. Six of the 12 included studies involved women whose symptoms were treatment‐induced, all of which concerned breast cancer survivors.17, 19, 26, 27, 28, 29 Three studies investigated the effect of MBT,19, 28, 30 five studies investigated CBT17, 18, 29, 31, 32 and four studies investigated BT.20, 26, 27, 33 All studies, except three had a waiting list control group.27, 29, 33 One study had a ‘care as usual’ control group,29 which consisted of breast cancer survivors during follow up with lifestyle advice on coping with hot flushes by a nurse specialist. The second study had a population of women experiencing natural menopause and had an active control group. The placebo activity in this case was individual leisure reading.33 The third study was conducted in breast cancer survivors and had an attention control group. The attention consisted of a general discussion of menopausal complaints with a nurse.27
Table 1

Table of study characteristics

Study author, year, study design, countryPopulation largest N analysed, population type, mean ageIntervention Type, Group or individual, program length, population tailored or generalComparisonOutcomes measured concept, scale
Mindfulness‐based intervention
Bower et al., (2015)19 RCT 65, BC survivors Mean age: 47 MAP, Group 6 × 2 h, weekly Tailored WLC

F/NS severity

Hoffman et al., (2012)28 RCT 214, BC survivors Mean age: 50 MBSR, Group 8 × 2 h, weekly + 2 h General WCL

Menopausal symptoms

Carmody et al., (2011)30 RCT 92, peri/post‐menopausal Mean age: 53 MBSR, Group 8 × 2.5 h, weekly General WCL

HF bother

HF intensity

Menopausal symptoms

Cognitive behavioural therapy‐based interventions
Duijts et al., (2012)17 RCT 173, BC survivors Mean age: 48 CBT, Group 6 × 1.5 h, weekly Tailored WLC

Menopausal symptoms

HF/NS bother

sex. freq. change

Ayers et al., (2012)18 RCT 129, peri/post‐menopausal mean age: 53 CBT, Group 4 × 2 h, weekly Tailored WLC

HF/NS problem rating

HF/NS frequency

Mann et al., (2012)29 RCT 88, BC survivors mean age: 54 CBT, Group 6 × 1.5 h, weekly Tailored CAU (BCFU)

HF/NS problem rating

HF/NS frequency

Keefer et al., (2005)31 RCT 19, perimenopausal Mean age: 51 CBT, Group 8 × 1.5 h, weekly Tailored WLC

HF frequency/2 weeks

HF/NS problem rating

Hunter et al., (1996)32 RCT24, menopausal Mean age: 52 CBT, Individual 4 × 1 h/6–8 weeks Tailored WLC

HF/NS problem rating

HF/NS frequency

Behavioural therapy‐based interventions
Lindh‐Ȧstrand et al., (2013)20 RCT 59, post‐menopausal Mean age 54.9 BT, Group 10 × 1 h/12 weeks Tailored WLC

HF frequency/24 h

VM symptoms and sexual behaviour

Fenlon et al., (2008)27 RCT 104, BC survivors Median age: 55 BT, individual 1 × 1 h General Att. C

HF frequency/week

HF severity

HF/NS problem rating

Menopausal symptoms

Fenlon et al., (1999)26 RCT 16, BC survivors Mean age: 48 BT, Individual 2 weekly. General WLC

HF frequency/24 h

HF/NS problem rating

Irvin et al., (1996)33 RCT 33, post‐menopausal Mean age 50.8 BT, Individual 1 × 1 h General Act. C

HF frequency/24 h

HF intensity

Act. C, active control group; Att. C, attention control group; BC, breast cancer; BT, behavioural therapy (relaxation); CAU, care as usual; CBT, cognitive behavioural therapy; HF, hot flush; MAP, mindfulness awareness programme; MBSR, mindfulness‐based stress reduction; NS, night sweats; VM, vasomotor.

Table of study characteristics F/NS severity Menopausal symptoms HF bother HF intensity Menopausal symptoms Menopausal symptoms HF/NS bother sex. freq. change HF/NS problem rating HF/NS frequency HF/NS problem rating HF/NS frequency HF frequency/2 weeks HF/NS problem rating HF/NS problem rating HF/NS frequency HF frequency/24 h VM symptoms and sexual behaviour HF frequency/week HF severity HF/NS problem rating Menopausal symptoms HF frequency/24 h HF/NS problem rating HF frequency/24 h HF intensity Act. C, active control group; Att. C, attention control group; BC, breast cancer; BT, behavioural therapy (relaxation); CAU, care as usual; CBT, cognitive behavioural therapy; HF, hot flush; MAP, mindfulness awareness programme; MBSR, mindfulness‐based stress reduction; NS, night sweats; VM, vasomotor. To measure hot flush frequency, the frequency subscale of the hot flush rating scale (HFRS scale) or similar diaries were used. Hot flush bother was most often measured by the HFRS subscale that measures bother by hot flushes (problem‐rating, distress and interference). Menopausal symptoms were measured using the Functional Assessment of Cancer Therapy – Endocrine Therapy Scale (FACT‐ES) and the Menopausal Quality of life scale (MENQOL). Both questionnaires contain psychosocial, physical, vaginal, sexual and vasomotor items. Sexual activity was measured by the habit subscale of the Sexual Activity Questionnaire (SAQ) and sexual behaviour subscale of the Women's Health Questionnaire (WHQ). An overview of the reported results of the main outcomes is given in the (Table S3).

Assessment of risk of bias

A high risk of performance bias was present for all studies, because blinding of CBT‐, BT‐ and MBT‐based interventions is not feasible (see Table S4). Consequently, the risk of detection bias was high because outcomes were patient‐reported.

Meta‐analysis of overall effect

A statistically significant benefit from psychological interventions was seen on short‐term hot flush bother (SMD −0.54, 95% CI −0.74 to −0.35, P < 0.001), short‐term menopausal symptoms (SMD −0.34, 95% CI −0.52 to −0.15, P < 0.001) and medium‐term hot flush bother (SMD −0.38, 95% CI −0.58 to −0.18, P < 0.001) (Table 2). [Correction added on 9 July 2018, after first online publication: there were miscalculations of the mean end point scores for hot flush bother and these have been corrected in the preceding sentence.] No statistically significant benefit from psychological interventions was seen on short‐term hot flush frequency (SMD −0.41, 95% CI −0.83 to 0.01, P = 0.05) or medium‐term hot flush frequency (SMD −0.21, 95% CI −0.89 to 0.26, P = 0.29). Heterogeneity was high for most outcomes. A meta‐analysis of sexual functioning was not feasible because only two studies reported on this outcome.17, 20 An overview of the exact data entered into the main meta‐analysis is shown in the (Table S5).
Table 2

Meta‐analysis for hot flush frequency, hot flush bother and menopausal symptoms (short‐ and medium‐term)

OutcomeNo. of studies N totalSMD (95% CI) P (overall effect) I 2 a/chi‐square/P (heterogeneity)
Short‐term (<20 weeks)
HF frequency6300−0.41 (−0.83 to 0.01)0.0565%/14.19/0.01
HF bother7568−0.63 to 0.80 to −0.46)<0.001a 0%/6.49/0.48
Menopausal symptoms3474−0.34 (−0.52 to −0.15)<0.001a 0%/1.46/0.48
Medium‐term (≥20 weeks)
HF frequency3234−0.31 (−0.89 to 0.26)0.2979%/9.55/0.008
HF bother5486−0.49 (−0.80 to −0.19)0.002a 63%/10.75/0.03
Menopausal symptoms2264−0.45 (−1.07 to 0.18)0.1683%/5.82/0.02

HF, hot flushes.

Statistically significant (<0.05).

Low: 0–24%, moderate: 25–49%, substantial: 50–74%, significant 75–100%.22

[Correction added on 9 July 2018, after first online publication: In table 1, the data for HF bother for short‐term (<20 weeks) and medium‐term (≥ 20 weeks) have been corrected.]

Meta‐analysis for hot flush frequency, hot flush bother and menopausal symptoms (short‐ and medium‐term) HF, hot flushes. Statistically significant (<0.05). Low: 0–24%, moderate: 25–49%, substantial: 50–74%, significant 75–100%.22 [Correction added on 9 July 2018, after first online publication: In table 1, the data for HF bother for short‐term (<20 weeks) and medium‐term (≥ 20 weeks) have been corrected.]

Publication bias

The Egger test result was >0.10 for all studies, indicating no proof of statistically significant publication bias. However the funnel plots showed some asymmetry, indicating that this result could be due to a limited number of studies per outcome (see Figure S1).

Subgroup analysis

A beneficial effect of psychological interventions was seen on short‐term hot flush bother in the subgroup treatment‐induced menopause (SMD −0.47, 95% CI −0.69 to −0.25, P < 0.001) as well as in the subgroup natural menopause (SMD −0.85, 95% CI: −1.11 to −0.59, P < 0.001) (see Figure S2). Benefit of psychological interventions was also seen on medium‐term hot flush bother for both the natural menopause subgroup (SMD −0.77, 95% CI −1.16 to −0.39, P < 0.001) as well as in the treatment‐induced menopause subgroup (SMD −0.32, 95% CI −0.64 to 0.00, P =0.05).

Adverse effects

Four studies reported on adverse effects of CBT, MBT and BT and did not encounter any adverse effects.18, 20, 28, 29

Discussion

Main findings

A small to moderate reduction of short‐ and medium‐term hot flush bother and short‐term menopausal symptoms by psychological interventions (i.e. CBT, BT and MBT) was found in the meta‐analysis. Hot flush frequency however, was not statistically significantly reduced by psychological interventions. Furthermore, the short‐ and medium‐term hot flush bother was reduced by psychological interventions in the breast cancer survivor subgroup and the natural menopause subgroup. However, medium‐term hot flush bother reduction was bordering on statistical significance in the breast cancer survivor subgroup. No adverse effects caused by psychological interventions were reported.

Strengths and limitations

This systematic literature review and meta‐analysis is the first to investigate and quantify the efficacy of CBT, BT and MBT on menopausal symptoms in both naturally occurring and treatment‐induced menopause in survivors of breast cancer with inclusion of recently published studies and novel mindfulness interventions. Furthermore, a large number of RCTs were included and subgroup analyses were possible for natural and treatment‐induced subgroups for most outcomes. An important aspect of this systematic literature review and meta‐analysis is that only patient‐reported outcomes were included, which reflect the actual inconvenience caused by hot flushes.23 A high level of heterogeneity was found in the meta‐analysis, probably because of the differences in populations (natural versus treatment‐induced) and possibly due to differences between interventions (e.g. type, duration). The level of heterogeneity was not of great concern because the aim of this systematic literature review and meta‐analysis was to answer the wider question about the effectiveness of psychological interventions as a whole, as they are all based on the similar principal of stressor impact reduction, in all menopausal women regardless of cause. Other limitations were the fact that some of the included RCTs were small (i.e. five of the twelve studies consisted of <60 participants in total) and possible presence of publication bias.

Interpretation

Hot flush bother versus hot flush frequency

As reduction of hot flush bother was greater than the reduction of hot flush frequency it could be that the main mechanism of action of psychological interventions is to modify cognitive appraisal of hot flushes, thereby increasing coping skills to reduce the impact of hot flushes.13 In the general population, women who report a low frequency of hot flushes can still experience substantial bother by hot flushes and vice versa.34 Frequency of hot flushes has been identified as being associated with bother by hot flushes.34 However, they were not interchangeable as other factors such as affect, symptom sensitivity, general health and sleep problems are also associated with the level of bother by hot flushes.34 So, reduction of bother by hot flushes might be the most appropriate measure of improved quality of life in women suffering from vasomotor symptoms.34, 35

Effectiveness in breast cancer survivors

Psychological interventions could be a valid strategy to reduce hot flush bother in breast cancer survivors. This is an important finding of the meta‐analysis as breast cancer survivors are contraindicated to use HRT, but report more frequent, more severe, more distressing and a longer duration of hot flushes compared with age‐matched controls or naturally menopausal women.6, 36, 37, 38

Lack of long‐term outcomes

No studies reported on long‐term (≥52 weeks) outcomes. The effect of a booster session on maintaining the effect of the intervention warrants further investigation. This could not be evaluated properly in the meta‐analysis because only two studies incorporated a booster session and did so within the short‐term period.17, 27

Lack of sexual outcomes

Only two of the 12 included studies reported on sexual outcomes.17, 20 The lack of sexual outcomes in current research stands in stark contrast to the fact that sexual functioning is shown to be severely impaired during menopause with 76% of menopausal women reporting sexual dysfunction.5, 39, 40, 41 A recent one‐armed pilot study aimed at improving sexual functioning in women with surgical menopause investigated the effect of an intervention combining MBT and sexual health education and found statistically significant improvement of sexual functioning.42 This suggest that psychological therapy could be an effective intervention for improving sexual functioning in menopause. Indeed, a review by Al‐Azzawi et al. concludes that nonpharmacological approaches, including psychological therapy, should be the first step in treating postmenopausal sexual dysfunction, before moving on to pharmacological options.43

Other causes of treatment‐induced menopause

Lastly, breast cancer treatment was the only cause for treatment‐induced menopause that was investigated in the included studies. However, there are more causes for treatment‐induced menopause such as risk‐reducing salpingo‐oophorectomy in women with high risk for ovarian cancer (e.g. BRCA1/2 mutation carriers). Risk‐reducing salpingo‐oophorectomy in BRCA1/2 mutation carriers has become a widely applied procedure causing early surgical menopause.44, 45, 46, 47 Next to an increased risk for developing ovarian cancer, BRCA1/2 mutation carriers also have an increased risk of developing breast cancer.48, 49, 50, 51, 52 About one‐third of BRCA1/2 mutation carriers who experience surgical menopause have had breast cancer and therefore have a contraindication for using HRT.53 This signifies the need for a safe, nonhormonal alternative for alleviating menopausal symptoms in groups with different causes of treatment‐induced menopause.

Conclusion

The need for nonhormonal alternatives to HRT has been firmly established following the publication of the Women's Health Initiative10 and considering the contraindication of HRT in breast cancer survivors. The results of this review suggest that psychological interventions could be a safe and effective treatment that reduces bother by hot flushes in all women experiencing symptoms associated with menopause, including breast cancer survivors. These findings support healthcare providers in offering psychological interventions to women who suffer from hot flushes and menopausal complaints, especially for women who will not be using HRT. However, larger trials with a longer follow‐up time are needed to confirm the (long‐term) effectiveness of psychological therapies. Furthermore, RCTs investigating the comparative effectiveness of CBT, BT and MBT are needed, as studies on this topic are scarce. The staggering lack of sexual outcomes in current research in conjunction with the fact that sexual functioning is severely impacted during menopause, emphasises that future research should focus on the effect of psychological interventions on sexual outcomes.

Disclosure of interests

None declared. Completed disclosure of interests form available to view online as supporting information.

Contribution to authorship

All authors (CvD, AS, MS, MM and GdB) were involved in the design and execution of the trial, analysis of the data and writing of the paper. CvD and AS contributed equally as first authors of the manuscript.

Details of ethical approval

For this study, no approval was required from a medical ethics committee as no experiments were done on human beings.

Funding

No funding was provided for this research. Figure S1. Funnel plots for short and medium term hot flush frequency, hot flush bother and menopausal symptoms including Egger test results. Figure S2. Forest plot of short‐term hot flush bother (subgroups natural versus treatment‐induced menopausal symptoms). Click here for additional data file. Table S1. Search terms. Table S2. Domains and scoring of Cochrane risk of bias tool22 Table S3. Outcomes and results per outcome type. Table S4. Risk of bias assessment as measured with the risk of bias tool from the Cochrane collaboration. Table S5. Transformed outcomes and results per outcome type as used in the meta‐analysis. Click here for additional data file. Click here for additional data file. Click here for additional data file. Click here for additional data file. Click here for additional data file. Click here for additional data file.
  51 in total

1.  Modeling hot flushes and quality of life in breast cancer survivors.

Authors:  K L Rand; J L Otte; D Flockhart; D Hayes; A M Storniolo; V Stearns; N L Henry; A Nguyen; S Lemler; J Hayden; S Jeter; J S Carpenter
Journal:  Climacteric       Date:  2010-05-07       Impact factor: 3.005

2.  Prevalence of sexual dysfunction in a cohort of middle-aged women: influences of menopause and hormone replacement therapy.

Authors:  C Castelo-Branco; J E Blumel; H Araya; R Riquelme; G Castro; J Haya; G Gramegna
Journal:  J Obstet Gynaecol       Date:  2003-07       Impact factor: 1.246

Review 3.  Menopausal Symptoms and Their Management.

Authors:  Nanette Santoro; C Neill Epperson; Sarah B Mathews
Journal:  Endocrinol Metab Clin North Am       Date:  2015-09       Impact factor: 4.741

4.  Effectiveness of mindfulness-based stress reduction in mood, breast- and endocrine-related quality of life, and well-being in stage 0 to III breast cancer: a randomized, controlled trial.

Authors:  Caroline J Hoffman; Steven J Ersser; Jane B Hopkinson; Peter G Nicholls; Julia E Harrington; Peter W Thomas
Journal:  J Clin Oncol       Date:  2012-03-19       Impact factor: 44.544

5.  Incidence of chemotherapy- and chemoradiotherapy-induced amenorrhea in premenopausal women with stage II/III colorectal cancer.

Authors:  Juefeng Wan; Ya Gai; Guichao Li; Zhonghua Tao; Zhen Zhang
Journal:  Clin Colorectal Cancer       Date:  2014-09-28       Impact factor: 4.481

6.  Mindfulness meditation for younger breast cancer survivors: a randomized controlled trial.

Authors:  Julienne E Bower; Alexandra D Crosswell; Annette L Stanton; Catherine M Crespi; Diana Winston; Jesusa Arevalo; Jeffrey Ma; Steve W Cole; Patricia A Ganz
Journal:  Cancer       Date:  2014-12-23       Impact factor: 6.860

7.  Reduced thermoregulatory null zone in postmenopausal women with hot flashes.

Authors:  R R Freedman; W Krell
Journal:  Am J Obstet Gynecol       Date:  1999-07       Impact factor: 8.661

8.  Health-related quality of life of african american breast cancer survivors compared with healthy African American women.

Authors:  Diane M Von Ah; Kathleen M Russell; Janet Carpenter; Patrick O Monahan; Zhao Qianqian; Eileen Tallman; Kim Wagler Ziner; Anna Maria Storniolo; Kathy D Miller; R Brian Giesler; Joan Haase; Julie Otte; Victoria L Champion
Journal:  Cancer Nurs       Date:  2012 Sep-Oct       Impact factor: 2.592

9.  The Cochrane Collaboration's tool for assessing risk of bias in randomised trials.

Authors:  Julian P T Higgins; Douglas G Altman; Peter C Gøtzsche; Peter Jüni; David Moher; Andrew D Oxman; Jelena Savovic; Kenneth F Schulz; Laura Weeks; Jonathan A C Sterne
Journal:  BMJ       Date:  2011-10-18

10.  Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.

Authors:  Richard M Brohet; Maria E Velthuizen; Frans B L Hogervorst; Hanne E J Meijers-Heijboer; Caroline Seynaeve; Margriet J Collée; Senno Verhoef; Margreet G E M Ausems; Nicoline Hoogerbrugge; Christi J van Asperen; Encarna Gómez García; Fred Menko; Jan C Oosterwijk; Peter Devilee; Laura J van't Veer; Flora E van Leeuwen; Douglas F Easton; Matti A Rookus; Antonis C Antoniou
Journal:  J Med Genet       Date:  2013-11-27       Impact factor: 6.318

View more
  4 in total

Review 1.  Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.

Authors:  Lisa Jeffers; Joanne Reid; Donna Fitzsimons; Patrick J Morrison; Martin Dempster
Journal:  Cochrane Database Syst Rev       Date:  2019-10-09

2.  Mobile web-based self-management program for breast cancer patients with chemotherapy-induced amenorrhoea: A quasi-experimental study.

Authors:  Jin-Hee Park; Yong Sik Jung; Ji Young Kim; Sun Hyoung Bae
Journal:  Nurs Open       Date:  2021-10-30

3.  Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis.

Authors:  C M van Driel; A Stuursma; M J Schroevers; M J Mourits; G H de Bock
Journal:  BJOG       Date:  2018-03-15       Impact factor: 6.531

4.  Exercise and Quality of Life in Women with Menopausal Symptoms: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Thi Mai Nguyen; Thi Thanh Toan Do; Tho Nhi Tran; Jin Hee Kim
Journal:  Int J Environ Res Public Health       Date:  2020-09-26       Impact factor: 3.390

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.